- Home
- / X4 Pharmaceuticals
X4 Pharmaceuticals
Stock Price
$0.5
2024-10-29
Market Capitalization
$83.9 M
2024-10-29
Revenue
$6.5 M
FY, 2025
X4 Pharmaceuticals Summary
Company Summary
- Overview
- X4 Pharmaceuticals (formerly known as Arsanis) is a biopharmaceutical company that provides drug development services. It specializes in discovering and commercializing therapeutics for the treatment of rare diseases of the immune system.
- Type
- Public
- Status
- Active
- Founded
- 2010
- HQ
- Boston, MA, US | view all locations
- Website
- https://www.x4pharma.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Art Taveras, Chief Scientific Officer
Mary Dibiase, Chief Operating Officer
LocationsView all
2 locations detected
Boston, MA HQ
United States
61 North Beacon Street, 4th Floor
Wien, Wien
Austria
Helmut-Qualtinger-Gasse 2
X4 Pharmaceuticals Financials
Summary Financials
- Revenue (Q1, 2026)
- $2.5M
- Gross profit (Q1, 2026)
- $1.9M
- Cash (Q1, 2026)
- $216.9M
- EBIT (Q1, 2026)
- ($20.3M)
- Enterprise value
- ($131.6M)